
News|Articles|September 10, 2024
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
Author(s)WCG Clinical
The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Trending on Applied Clinical Trials Online
1
Worldwide Clinical Trials to Acquire Catalyst Clinical Research, Expanding Oncology and FSP Capabilities
2
How Real-World Evidence Will Change Trials Without Replacing Them
3
What 2026 Will Demand From Clinical Operations: Rethinking Efficiency, Access, and AI
4
ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline
5